This document provides an agenda for the Cell Line Asia conference taking place on May 20-21, 2015 in Singapore. The conference will focus on strategies and technologies for developing robust cell lines at high quality and scale for biopharmaceutical production.
The agenda lists over 30 speakers from companies in China, USA, and Singapore who will present on topics such as novel cell line development platforms, high-throughput analytical methods, media optimization, glycosylation analysis, bioprocess design and scale-up strategies, and next-generation bioprocessing trends. There will also be panel discussions, networking events, and two pre-conference workshops on design of experiments applications and bioprocess technology transfer. The conference is aimed at cell line developers
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
The 4th Annual Biomanufacturing Conference is taking place on the 20 - 23 May 2014 at Grand Hyatt, Shanghai. A must go event for you to get the latest updates from the industry, to learn more of the latest developments and best practices in increasing production, enhancing quality and optimizing operations in the biomanufacturing industry.
Key Conference Topics
GMP & Standards
Successful Partnerships, Investment & Financing
Effective Planning, Facility Design & Development
Improving Operations & Supply Chain Management
Cost Effective Single-Use Systems & Technology Transfer
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
The 4th Annual Biomanufacturing Conference is taking place on the 20 - 23 May 2014 at Grand Hyatt, Shanghai. A must go event for you to get the latest updates from the industry, to learn more of the latest developments and best practices in increasing production, enhancing quality and optimizing operations in the biomanufacturing industry.
Key Conference Topics
GMP & Standards
Successful Partnerships, Investment & Financing
Effective Planning, Facility Design & Development
Improving Operations & Supply Chain Management
Cost Effective Single-Use Systems & Technology Transfer
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
Current issues and challenges in demonstrating QbD Korea 1 December 2014Ajaz Hussain
2014 Ministry of Food and Drug Safety (MFDS) International Workshop: Quality by Design (QbD) Implementation and Regulatory Challenges in theNew Pharmaceutical Quality ParadigmDecember 1 -2, 2014, Grand Hilton Hotel, Seoul, Korea.
Legitimate pharmaceutical community has practiced QbD for decades; however in ways that vary undesirably.
Demonstration of QbD is multifaceted.
There are serious consequences …in ways that can vary undesirably…
The consequence of “Cheating by Design” are almost always catastrophic.
Perhaps we need to view QbD applications/submissions as an additional layer of protection; to gauge the Culture of Quality.
Legitimate efficiency – is a key business driver, good for the patients, and the society overall.
Proposed ICH Q12: Regulatory Dossier - “regulatory commitments”.
Pharmaceutical Quality System aspects (ICH Q10) – risk and knowledge management system.
Post-Approval Change Management Plans and Protocols.
A reminder of the approach utilized for FDA’s PAT Guidance, Comparability Protocol and Team Approach.
Must focus on integrated implementation.
Team-building and training for Review, Compliance & Inspection functions.
Recognize that QbD Applications/submissions serve as an additional layer of protection; to gauge the Culture of Quality.
The Avoca Quality Consortium Summit, held May 8-9, 2013, in
Princeton, NJ, was the Second Annual meeting for The Avoca
Group’s Quality Consortium, a cooperative effort that brings
together quality, outsourcing, and operational professionals
from Member pharma, biotech, and CRO organizations to
accelerate the development of a best-practices approach to
quality management and CRO oversight.
Currently, the Avoca Group’s Quality Consortium includes
26 Members: 16 pharma/biotech companies and 10 Contract
Research Organizations (CROs). The corporate sponsors of the Quality Consortium are Eli Lilly and Company and Pfizer, Inc. ICON Clinical Research was the corporate sponsor of the May Summit.
Special thanks to our Executive Summary Sponsor,
inVentiv Health Clinical.
Oral Drug Formulation Innovations 2014Simon Curtis
The Oral Drug Formulation Innovations Summit will examine and showcase the industry's latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability. Leading global formulation experts in both industry and academia will share unique strategies on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations. Additionally, innovative strategies to significantly reduce product development timelines will be shared, and the latest regulatory requirements will be discussed.
In today’s healthcare industry, medicine is becoming more and more personalized with patient focused approach. To drive such a personalized medicine avenue, Biomarker is a good example anda leading contract research organizations (CRO) like CMIC, Inc. have a responsibility to provide bioanalytical data meaningful enough for advanced medicines.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
P 141 pre-filled syringes america revisedAlia Malick
The global prefilled syringe market is estimated to reach $6.9bn by 2018. This figure is reflective of manufacturers striving to improve their technologies to meet the increasing number of biologic drugs reaching the market. The rising demand for prefilled syringes is driving the manufacturers to introduce improvements in technology and with the focus still on the safety for the user, innovation improvements for device development and ease of use for the patient are key areas to be addressed.
SMi’s leading prefilled syringes conference will focus on a number of hot talking points that will no doubt cause controversy and debate and on reflection open the floor to discussion in our breakout sessions. In addition, with a new competitive market just around the corner for biosimilars we look at this new session for 2015 in addition to the vision and benefit of lyophilisation in a prefilled syringe.
Biomanufacturing in China: Technologies and Facility DesignRita Barry
Join us as we DISCOVER, ANALYZE and LEARN the current state of the global biomanufacturing industry and the future growth potential and recent developments in Asia.
Some of the Key Highlights You Won’t Want to Miss Include
USA
Smart & Flexible Manufacturing Solutions in Multi-Product Facilities
Franz Walz, Executive Director Global Manufacturing, Science and Technology & Network Coordination, BOEHRINGER INGELHEIM
EUROPE
MAb Manufacturing Facilities for China & Automated Single-Use Processing to Bring Control & Flexibility to Manufacturing
Pauline Nicholson, Global Product Manager, Allegro Single-Use Systems, PALL
Niels Guldager, Senior Technology Partner, NNE PHRAMAPLAN
KOREA:
How to Bring Global Biopharmaceutical Capability through its Fully-Integrated Production Facilities?
Jeremy Caudill, Global VP Business Development, SAMSUNG BIOLOGICS
SINGAPORE
What do Investors Look for When Investing in Biologics Manufacturing?
Steven Lee, Global Head of Biologics Tech Operations & Managing Director, DR. REDDY'S LABORATORIES
INDIA
Developing a Multiproduct Facility for Biosimilars & Engineering & Biomanufacturing of Enzymes for Different Applications
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals,
CADILLA PHARMACEUTICALS
Ravindra Wagh, Vice President, ZYDUS BIOLOGICS
Rajeev Soni, Senior Manager, R&D, NOVOZYMES
HONGKONG
What are the Experiences & What is the Future for the Investors in the Biomanufacturing Space?
Ramesh Rajentheran, Head of Asian Healthcare Investment Banking, BARCLAYS
Jason Mann, Managing Director, FENEX CAPITAL MANAGEMENT
INDONESIA
Improving Quality Control & Maintenance of Global Biological Product Distribution
Galatia Chandra, Head of Sales & System, Global Operation, KALBE INTERNATIONAL PTE LTD
http://www.biomanufacturing-asia.com
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
Current issues and challenges in demonstrating QbD Korea 1 December 2014Ajaz Hussain
2014 Ministry of Food and Drug Safety (MFDS) International Workshop: Quality by Design (QbD) Implementation and Regulatory Challenges in theNew Pharmaceutical Quality ParadigmDecember 1 -2, 2014, Grand Hilton Hotel, Seoul, Korea.
Legitimate pharmaceutical community has practiced QbD for decades; however in ways that vary undesirably.
Demonstration of QbD is multifaceted.
There are serious consequences …in ways that can vary undesirably…
The consequence of “Cheating by Design” are almost always catastrophic.
Perhaps we need to view QbD applications/submissions as an additional layer of protection; to gauge the Culture of Quality.
Legitimate efficiency – is a key business driver, good for the patients, and the society overall.
Proposed ICH Q12: Regulatory Dossier - “regulatory commitments”.
Pharmaceutical Quality System aspects (ICH Q10) – risk and knowledge management system.
Post-Approval Change Management Plans and Protocols.
A reminder of the approach utilized for FDA’s PAT Guidance, Comparability Protocol and Team Approach.
Must focus on integrated implementation.
Team-building and training for Review, Compliance & Inspection functions.
Recognize that QbD Applications/submissions serve as an additional layer of protection; to gauge the Culture of Quality.
The Avoca Quality Consortium Summit, held May 8-9, 2013, in
Princeton, NJ, was the Second Annual meeting for The Avoca
Group’s Quality Consortium, a cooperative effort that brings
together quality, outsourcing, and operational professionals
from Member pharma, biotech, and CRO organizations to
accelerate the development of a best-practices approach to
quality management and CRO oversight.
Currently, the Avoca Group’s Quality Consortium includes
26 Members: 16 pharma/biotech companies and 10 Contract
Research Organizations (CROs). The corporate sponsors of the Quality Consortium are Eli Lilly and Company and Pfizer, Inc. ICON Clinical Research was the corporate sponsor of the May Summit.
Special thanks to our Executive Summary Sponsor,
inVentiv Health Clinical.
Oral Drug Formulation Innovations 2014Simon Curtis
The Oral Drug Formulation Innovations Summit will examine and showcase the industry's latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability. Leading global formulation experts in both industry and academia will share unique strategies on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations. Additionally, innovative strategies to significantly reduce product development timelines will be shared, and the latest regulatory requirements will be discussed.
In today’s healthcare industry, medicine is becoming more and more personalized with patient focused approach. To drive such a personalized medicine avenue, Biomarker is a good example anda leading contract research organizations (CRO) like CMIC, Inc. have a responsibility to provide bioanalytical data meaningful enough for advanced medicines.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
P 141 pre-filled syringes america revisedAlia Malick
The global prefilled syringe market is estimated to reach $6.9bn by 2018. This figure is reflective of manufacturers striving to improve their technologies to meet the increasing number of biologic drugs reaching the market. The rising demand for prefilled syringes is driving the manufacturers to introduce improvements in technology and with the focus still on the safety for the user, innovation improvements for device development and ease of use for the patient are key areas to be addressed.
SMi’s leading prefilled syringes conference will focus on a number of hot talking points that will no doubt cause controversy and debate and on reflection open the floor to discussion in our breakout sessions. In addition, with a new competitive market just around the corner for biosimilars we look at this new session for 2015 in addition to the vision and benefit of lyophilisation in a prefilled syringe.
Biomanufacturing in China: Technologies and Facility DesignRita Barry
Join us as we DISCOVER, ANALYZE and LEARN the current state of the global biomanufacturing industry and the future growth potential and recent developments in Asia.
Some of the Key Highlights You Won’t Want to Miss Include
USA
Smart & Flexible Manufacturing Solutions in Multi-Product Facilities
Franz Walz, Executive Director Global Manufacturing, Science and Technology & Network Coordination, BOEHRINGER INGELHEIM
EUROPE
MAb Manufacturing Facilities for China & Automated Single-Use Processing to Bring Control & Flexibility to Manufacturing
Pauline Nicholson, Global Product Manager, Allegro Single-Use Systems, PALL
Niels Guldager, Senior Technology Partner, NNE PHRAMAPLAN
KOREA:
How to Bring Global Biopharmaceutical Capability through its Fully-Integrated Production Facilities?
Jeremy Caudill, Global VP Business Development, SAMSUNG BIOLOGICS
SINGAPORE
What do Investors Look for When Investing in Biologics Manufacturing?
Steven Lee, Global Head of Biologics Tech Operations & Managing Director, DR. REDDY'S LABORATORIES
INDIA
Developing a Multiproduct Facility for Biosimilars & Engineering & Biomanufacturing of Enzymes for Different Applications
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals,
CADILLA PHARMACEUTICALS
Ravindra Wagh, Vice President, ZYDUS BIOLOGICS
Rajeev Soni, Senior Manager, R&D, NOVOZYMES
HONGKONG
What are the Experiences & What is the Future for the Investors in the Biomanufacturing Space?
Ramesh Rajentheran, Head of Asian Healthcare Investment Banking, BARCLAYS
Jason Mann, Managing Director, FENEX CAPITAL MANAGEMENT
INDONESIA
Improving Quality Control & Maintenance of Global Biological Product Distribution
Galatia Chandra, Head of Sales & System, Global Operation, KALBE INTERNATIONAL PTE LTD
http://www.biomanufacturing-asia.com
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
The successful development of a biosimilar presents unique challenges compared to that of an innovator biologic. In particular, one must prove the biosimilar candidate's structural and functional differences do not have a meaningful impact on the clinical safety and efficacy profile already established for the innovator. Comprehensive and rigorous analytical testing to assess biosimilarity is thus the foundation upon which the successful development of a biosimilar begins.
The 2015 Bioprocessing Summit plans to unite 750+ attendees from 30+ countries for five days of inspiring presentations and solutions. The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
This leading bioprocess meeting is hosted in Boston each summer. Hundreds of bioprocess professionals come together each year at the Summit to share practical solutions for today’s bioprocess challenges with researchers from around the world.
Spanning five days, the 2015 meeting includes 12 conference programs, 8 training seminars and 10 short courses.
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Bioprocessing of Advanced Cellular Therapies CongressTony Couch
Last opportunity to get onto the programme.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
By choosing Covance as a single, centralized CMC analytical laboratory, you can obtain higher quality analytical data more efficiently and at lower cost/fewer resources than by working with multiple providers/CMOs. This analytical data is the key to knowledge and quality risk management throughout the product lifecycle.
The Bioprocessing Summit
August 18-22, 2014 | Boston, MA
http://www.bioprocessingsummit.com
The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line
selection to bioproduction. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
The Bioprocessing Summit continues to grow, and now comprises 12 distinct meetings in one event, including cell
culture, purification, bioproduction, quality, formulation, and novel biotherapeutic formats. The Summit also features small-group breakout discussions, networking in the busy exhibit hall, an extensive poster display, and an array of in-depth short courses and training seminars. For the full listing of speakers at this year's Summit, please click here.
This leading bioprocess meeting is hosted in Boston each summer along the lively and cosmopolitan harbor
waterfront. Hundreds of bioprocess professionals come together each year at the Summit to share practical
solutions for today’s laboratory challenges with researchers from around the world. Please visit the website www.bioprocessingsummit.com for more information and to register.
Introduction to Bioprocessing Sample SlidesPeteDeOlympio
Introduction to Bioprocessing
Monday, January 19, 8:30 AM-5:30 PM – Tuesday, January 20, 8:30 AM-12:30 PM
View sample slides
CHI’s Introduction to Bioprocessing training seminar offers a comprehensive survey of the steps needed to produce today’s complex biopharmaceuticals, from early development through commercial. The seminar begins with a brief introduction to biologic drugs and the aspects of protein science that drive the intricate progression of analytical and process steps that follows. We then step through the stages of bioprocessing, beginning with the development of cell lines and ending at the packaging of a finished drug product. The seminar also explores emerging process technologies, facility design considerations and the regulatory and quality standards that govern our industry throughout development. The important roles played by the analytical and formulation in developing and gaining approval for a biopharmaceutical are also examined. This 1.5-day class is directed to attendees working in any aspect of industry, including scientific, technical, business, marketing or support functions, who would benefit from a detailed overview of this field.
For full details visit chi-peptalk.com/peptalk_content.aspx?id=140088&libID=140059
The conference will provide an interactive networking forum to both further develop and answer your queries through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, poster presentation sessions, expert led case study presentations, a high-level panel discussion, a round table discussion session, and interactive Q&A sessions from a 40-strong speaker faculty examining topics on 4 separate tracks outlined below.
What's new this Year?
NEW LOCATION - Hong Kong.
PLASMA FRACTIONATION TECHNOLOGY WORKSHOP.
REGULATOR’S FORUM - meet Global and Asian regulatory experts for plasma and blood products.
GLOBAL EMERGING MARKETS Self Sufficiency Case Studies: China, India, Iran and more.
INSIGHTS to the first South East Asian plasma fractionation plant.
No other Bioplasma event can get you one-to-one access to senior decision-makers from both the international and regional Bioplasma industry.
5th Annual Pre-Filled Syringes East CoastTeri Arri
Building on the success of previous sell-out shows, SMi Group is delighted to announce the return of the 5th annual conference and exhibition: Pre-Filled Syringes - East Coast, taking place on April 11th – 12th 2018 in Boston, Massachusetts, USA.
A rise in chronic diseases, improvements in technology and a growing demand for easy to use drug administration products has in recent years, created a booming Pre-Filled Syringes industry.
Some notable areas of increased attention have been the broader trends for combination products and biologics, as well as the move towards digital health and improving patient adherence due to increased self-administration figures. As well as these areas of lucrative opportunity, there are still several ongoing challenges that the key-thought leaders are battling to overcome such as chemical compatibility, user safety, high-volume and highly viscous formulation, and non-compliance.
Pre-Filled Syringes East Coast will once again play host to an international audience of drug delivery, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the prefilled industry, helping attendees to secure global success for their PFS device.
Factors to keep in mind when you’re considering cloud storage services.Rita Barry
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, I’ve dedicated the focus of today’s discussion to the more popular cloud storage services—such as Dropbox, Box, OneDrive—which are also known as hosted, off premise solutions.
Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration
www.rkon.com
Carve-outs and Mergers and Acquisitions place unique demands on IT. How can y...Rita Barry
Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit — all to ensure a successful “day one.”
Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services.
Top Industry Issues to Be Discussed Include:
Benchmarks and lessons from World Class Tertiary Hospitals
Insights on clinical and operational excellence
Investment in Tertiary Hospital Services and achieving financial success
Streamlining outpatient services
Advanced consultative care & remote monitoring of patient health
Latest technology transforming patient accessibility, care and experiences
Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including:
Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore
Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines
Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia
Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia
Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India
Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam
Grace Siew Wah Lim, Chief Financial Officer, KK Woman’s and Children’s Hospital, Singapore
Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines
Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia
David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong
Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore
Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong
Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan
Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea
http://www.tertiaryhospitalservices.com
As you know, pharma compliance is a critical issue, particularly in China. The Chinese government’s recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages
To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit
(Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain.
Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits.
Your expert speaker faculty includes:
• Leon Wang, Vice President, AstraZeneca China
• Heike Deters, Head of Compliance, Bayer Healthcare China
• Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council People’s Republic of China
• Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie
• Gareth Lee, General Counsel & Head of Compliance APAC, Allergan
• Cristopher Landrito, Regional Compliance Manager APAC, Merck
• David Shen, General Counsel & VP Legal, AstraZeneca China
• Dr Wu Ke, President, Shanghai BravoBio
• Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis
• Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson
http://www.pharmacompliance-china.com
IBC’s OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC – a crucial element to achieve global success.
http://www.otcpharmaasia.com
The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities.
Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country.
The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery.
It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.
For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading.
Not only that, we will answer key questions of the post trade industry including:
• Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia?
• Will T2S lead to a migration of all financial players to ISO 20022 in Europe?
• What are the impacts of Hong Kong Shanghai Stock Connect on Asia’s economy and the global financial markets?
• What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2?
• Are CCPs all equal? Can we quantify the benefits of moving to a CCP?
• How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits?
With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access.
Download the brochure <link> now to identify new trends and opportunities in development and commercialization in the region.
ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asia’s markets.
Featured sessions from top industry thought leaders:
Market Trends and Drivers in the Region
• James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore
What You Need to Know When Marketing Oncology Drugs
• Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK
Successful Market Access Strategies for Oncology Drugs
• Sameer Agarwal, Senior Vice President, Business Center Strategic
Marketing, Fresenius Kabi Deutschland GmbH, Germany
Clinical Engagement for Successful Oncology Products
• Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India
http://www.oncologyasia.com
The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. <China Money Network, 28 July 2014)
The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBC’s Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders:
Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong
Update Speaker from Gladys, ICBC, Singapore
Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore
Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines
Other Key Topics Addressed Include:
• RMB Policy Liberalization
• Investing in RMB Capital Markets
• RMB Cross-Border Settlements
• Developing of Offshore RMB Operations
View more at http://www.offshorermbseminar.com
A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asia’s longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy.
The key topics to be covered at the event include:
Regulatory Update and Accelerating Access to New market
o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer
Building Brand Awareness and Delivering New Products with a Cost Effective Strategy
o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck
Managing Sale Force Effectiveness and Innovative Channels for Generics Products
o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals
Establishing Partnerships to Add Value and Build Market Share
o Philip Cox, President Director, PT Takeda Indonesia
Innovative Models and Super Generics for Prolonging Product Life Cycles
o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical
IBC’s Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives.
Key Conference Themes:
Updates on Regulation and the Road Towards Universal Healthcare Coverage
Hospital Management & Cutting Edge Healthcare Delivery Standards
Digital Marketing and Telehealth Solutions
Healthcare Infrastructure Projects, Investments & Development
Generics & Access to Medicine
Public-Private Partnerships & Collaboration
Why You Must Attend This Year’s Event
Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy
Discover partnerships and investment opportunities in Indonesia
Hear different case studies from major hospitals, insurance and pharmaceutical companies
Meet and exchange business cards with your peers during the networking sessions
Learn how to deliver safe and quality healthcare from other Asian countries
Medical Affairs teams in Asia’s diverse markets need to collaborate with R&D and understand the science, the business and the regulations. They need to constantly think strategically and communicate effectively.
• How can Medical Affairs teams be even more impactful in enhancing your company’s scientific reputation?
• How can you better communicate the value of your products to KOLs and Healthcare professionals?
• What makes a successful Medical Affairs team in Asia?
Get the answers and more at the 3rd MEDICAL AFFAIRS FORUM ASIA {link} - the region’s longest running strategy forum where leading medical affairs professionals share best practices, discuss common issues and learn from industry experts to enhance scientific reputation and better communicate the value of products to KOLs.
http://www.pharmaconasia.com/medical-affairs-forum-asia
PharmaCon - Pharmaceutical Congress Asia 2014 Rita Barry
The Leading Event Bringing 4 Successful Events Under 1 Roof!
The Pharmaceutical Congress Asia recognizes the importance of strong partnerships to drive innovation, development and winning products and services in Asia’s growing pharmaceutical industry. Packed with case studies from market leaders, four agendas will unite to create a hub of research, innovation, improved regulatory frameworks, best practice business, marketing and distribution models that will define Asia’s pharmaceutical future.
http://www.pharmaconasia.com
The Most Comprehensive Coverage of China’s Evolving Biologics Market
________________________________________
20 Case Studies ● Keynote from China SFDA Official
17 New Data Presentations ● Panel Discussions on Biosimilar and Analytical Methods
• Harness novel cell line technologies and approaches for improved developability and upstream processing
• Enhance analytical capabilities with new characterization and specification methods
• Benchmark your biosimilar program with case studies and new data on development and production
• Meet complex drug product and manufacturing challenges with new facility technologies and designs
http://www.ibclifesciences.com/bpichina
We’re pleased to announce that the Conference and Workshop programme for ISPE Singapore is ready to view on www.ispesingapore.org
FINAL BROCHURE NOW AVAILABLE FOR DOWNLOAD HERE!
This year, you’ll find:
• 90% NEW & 50% MORE Speakers than in 2013
• Over 34 presenters sharing their case studies and experience
• Choose from 36 hours of Learning, 6 hours of Networking Across the Plenary Conference & 9 practical workshops
• The latest solutions at the ISPE Singapore Exhibition on 23-24 June
• And don’t forget to sign up for the Site Visit to MSD Singapore Plant Extension!
Build your own agenda from 3 concurrent sessions:
Sunday 22 June (1.30-5.30pm):
A: Quality / Validation
B: Operational Excellence
C: Bio / Sterile / Clean Utilities
Monday 23 June (2.00-5.45pm):
D: Tech Transfer / Process Validation
E: QBD / PAT
F: Sterile Operations
Tuesday 23 June (9.00-3.30pm):
G: Quality / Audit / Regulatory
H: Operational Excellence / Lean Manufacturing
J: Biologics
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
1. Part of
IBC
LIFE SCIENCES
Produced by:
www.celllineasia.com
Supporting
Association:
Media Partners:
Exhibitor:Associate Sponsor: Session Spotlight Sponsors:
International Marketing
Partner:
Pengfei Zhou
CEO,
Wuhan YZY Biopharma,
China
Accelerating Robust Cell Line Generation with High Quality
& Scalability in Production
2015 Expert Faculty Include: Key Strategies for Increasing
Productivity & Quality in your Cell Line
Development
Reduce Timelines in your Clone
Selection & Screening process
Scale-Up Strategies & Next-Generation
Bioprocessing Insights
Getting the Most out of Transient and
Stable Expression Systems
Omics Approaches to Enhance Cell
Culture Performance and Product
Quality
Optimising Glycosylation for Enhanced
Properties
Individual Optimization of Chemically
Defined Media
Critical Quality Attributes (CQA) &
Quality by Design (QbD)
Implementation Strategies
New Topics for 2015:
Xiang Yang Zhu
CEO,
Huaota Biopharm,
China
Scott Liu
CEO,
Henlius
Pharmaceuticals, USA
Pei Ye
Vice President,
Beijing Mabworks
Biotech, China
Zhiwei Pan
Senior Director,
Cell Culture Process
Development,
Livzon mAbpharm,
China
Pre-Conference Workshops Not to be Missed | 19 May 2015
Best Practices in Process Technology Transfer
and cGMP Manufacturing
Achieving Operational Excellence in
Bioprocessing: Design of Experiments (DoE)
Applications for Cell Culture
A
B
PLUS! An Exclusive
Post-Conference
Special Focus Day | 22 May 2015
Cutting Edge Trends in
Antibody Development
Peng Wang
President of R&D,
Yabao
Pharmaceutical
Group, China
Life
Sciences
2. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
CONFERENCE DAY ONE
20 May 2015 | Wednesday
12:40 Integrating Multi-Omics Analysis & In Silico Modelling of
CHO Cells for Enhancing Cell Culture Performance and
Product Quality
• Mammalian systems biotechnology framework
• Integrated bioinformatics platform for multi-omics profiling and
analysis
• Genome-scale metabolic/regulatory modelling and in silico
analysis of CHO cells
• Characterizing cell cultures and identifying metabolic and
regulatory signatures for cell line development
Dong-Yup Lee, Assistant Professor, Department of Chemical
and Biomolecular Engineering, NUS, Singapore
1:10 Networking Luncheon & VIP Tables
VIP Table 1: Peng Wang, President of R&D,
Yabao Pharmaceutical Group, China______________________________________________________________________________________________
VIP Table 2: Zou Ping, Vice Director,
Shanghai CPGJ Pharma, China______________________________________________________________________________________________
VIP Table 3: John Xu, CSO, Shanghai Benemae Pharma &
VP, Shanghai Mabicine, China______________________________________________________________________________________________
Exchange business cards and have an informal chat with the
above guests during the networking lunch!
2:30 Roundtable Discussions
Each leader will facilitate the discussion for 45 minutes. Leaders will
then share key takeaways on the stage for 5 minutes each. Choose your
table now! Email sonia.jaya@ibcasia.com.sg______________________________________________________________________________________________
Novel Cell Line Development and Bioprocess Approaches
for Increased Speed, Titer and Product Quality
Cheng Zhang, CSO, Gmax Biopharm, China______________________________________________________________________________________________
Strategies on Raw Material and Supplier Management
for Efficient, Cost-effective Biopharmaceutical Production
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA______________________________________________________________________________________________
Applying Essential QbD Strategies in Cell Culture and
Bioprocess Deveopment for Biopharmaceuticals
Hung Fai Poon, Director,CellCulture, Hisun Pharmaceuticals,
China
3:30 Afternoon Networking & Refreshment Break
Cell Culture Media for Optimized Growth
4: 10 Individual Optimization of Chemically Defined Media
• Best practices in media formulation, optimization and preparation
• Implementing the most optimal conditions
• How can the host cell be made to effectively preadapt to
suspension and serum-free media, and thus cutting short the
overall developmental timeline?
• Optimizing medium for a fed batch culture or develop an
optimized growth medium for large scale production
• Analytical tools and high-throughput protocols in increasing cell
densities
Chuan He, Process Development, Senior Scientist,
Beijing Mabworks Biotech, China
Optimising Glycosylation
4:50 High Throughput & High Resolution Glycosylation
Analysis Throughout Bioprocess Development for
Improved Quality
• How does the glycosylation profile impact quality of bioproducts
• How glycosylation variation can affect structure, effector function
and product stability
• Importance of glycosylation analysis in bioprocess development
• Strategies and techniques to incorporate glycosylation analysis
in bioprocessing for high quality products
DrPeiqingZhang, AssistantProfessor,DepartmentofAnatomy,
Yong Loo Lin School of Medicine, NUS Singapore
5:30 Chairperson’s Closing Remarks &
End of Conference Day One
6:00 Networking Cocktail
VIP 1: Scott Liu, CEO, Henlius Pharmaceuticals, USA______________________________________________________________________________________________
VIP 2: Feng Tian, Head and Director, Ambrx China______________________________________________________________________________________________
VIP3 : Wen-Chen Suen, Chief Scientific Officer, Biologics
Division, HEC Pharm, China
Exchange business cards and visit the above guests!
KEYNOTEPANELCEOPANEL
08:00 Registration Opens & Morning Coffee
08:50 Welcome Address from IBC Asia & Speed Networking
09:00 Chairperson’s Opening Remarks
Abdullah Baaj, CEO, Boston Oncology, USA
Biopharma Visionary Keynote Sessions
9:05 Global Biopharma Outlook: Opportunities & Challenges
2015 & Beyond
• Macro-analysis of the current biopharma environment and market
drivers
• What are the constraints, opportunities and challenges?
• Innovation in the industry – who is taking the lead? Who are the
silent players?
• How is Big Pharma and Biologics Majors reacting to the Biosimilars
opportunity?
• Where are the Next Generation MaBs Biosimilars likely to come
from?
• Is there money to be made from Biosimilars?
• Pros and cons of serving multiple growing markets
Moderator: Yariv Hefez, Vice President Business Development,
Portfolio Management, Strategy and Partnering, Biosimilars
Unit, Merck Serono, Switzerland
Panelists:
Abdullah Baaj, CEO, Boston Oncology, USA
Racho Jordanov, President & CEO, JHL Biotech, Taiwan
Richard O’Keeffe, Executive Director, International Quality –
Japan-Asia-Pacific (JAPAC) Regional Quality Head, Amgen,
Singapore
9.45 Cutting Edge Insights into China’s Growing Biotech
Market
• Perspectives on China’s biotech policies, regulation and markets
• Can Chinese Biosmilar brands compete effectively against Indian
and Korean Biosimilars globally?
• Information on the local regulatory and Government policies
• Private vs publicly funded biopharma research and development
• Growth strategies and key for success in a highly competitive
market
Moderator: Shou-Bai Chao, SeniorVicePresident,BioVentures,
Global Operations, AstraZeneca, China
Panelists:
Joe Zhou, CEO, Walvax Group, China
Li Shi, CEO, Shanghai Zerun Biotechnology, China
Michelle Yu Xia, Chairman, President & CEO,
Akeso Biopharma, China
Scott Liu, CEO, Henlius Pharmaceuticals, USA
10.25 China’s Evolving Biopharma Policies & Regulations
• Update on China’s Biosimilars guidelines and biologic regulations
• Biomanufacturing standards
• Testing, GMP Inspections and product quality
SeniorRepresentative, China Food and Drug Administration
(CFDA), China
10:50 Morning Networking and Refreshment Break
Advances in Clone Screening and Selection
11: 30 Chairperson’s Opening Remarks
Pengfei Zhou, CEO, Wuhan YZY Biopharma Co Ltd, China
11:40 Efficient Screening Strategies to Select Clones & Reduce
Timelines
• Current challenges in streamlining selection and clonal isolation
• Review of latest technologies to overcome these challenges and
suggestions to reduce timelines
• Combining image processing and document tracking system for
effective clone- picking
• Clonal cell lines selection using Cell MetricTM CLD
Chaomei He, PrincipalScientist, Momenta Pharmaceuticals,
USA
Analytical Strategies for Increased
Quality in Bioproduction
12:10 High-Throughput (HTP) Analytical Platforms to Assess
Product Quality Attributes in Cell Lines
• What are the major challenges met when using these HTP
technologies, especially in mammalian cell line development?
• Novel HT technologies available for increased productivity and
quality
• HTP analytical assays to facilitate product quality in the early
stage of clone screening to hasten process development
Senior Representative, Lonza
GOVERNMENT
ADDRESS
3. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
CONFERENCE DAY TWO
21 May 2015 | Thursday
9:00 Chairperson’s Opening Remarks
HungFaiPoon, Director,CellCulture, HisunPharmaceuticals,
China
Novel Cell line Development Platforms &
Expression Systems
9:05 Cell Line Development Platforms: AnalyzingVarious Cell
Line Expression Platforms
• Review of mammalian vs non-mammalian expression systems
• Comparison of safety, cost and quality of various cell lines
• Future trends in moving away from CHO cell lines
• Novel expression systems – Case study of Amgen’s targeted
integration approach
Dayou Liu, Senior Scientist, Amgen, USA
9:40 Getting the Most Out of Stable and Transient
Expression Systems
• Review and discussion of stable vs transient cell lines- pros and
cons
• Overcoming the regulatory hurdles involved
• Recent advances in transient transfection and cell culture methods
• Suspension cell culture lines vs in plated cell lines
Panelists:
Xiang Yang Zhu, CEO, Huaota Biopharm, China
Dayou Liu, Senior Scientist, Amgen, USA
Cheng Zhang CSO, Gmax Biopharm, China
10:20 Morning Networking and Refreshment Break
10:50 Using Targeted Genome Engineering to Advance CHO
Cell Technology
• Horizon’s GS Null cells
~ Industry need
~ Engineering
• Critical Quality Attributes (CQAs) in cell production systems:
what makes a “Good CHO”?
• Using engineering to improve these CQAs
~ Different engineering technologies
~ Different targets
~ Large scale engineering in one line
• Future plans to continue revolutionizing Cell line development
in Bioproduction
Dr Jamie Freeman, Bioproduction Product Manager,
Horizon Discovery, U.K
11:30 Overcoming the ‘Position Effect’– Targeting Integration
into Chromosomal Hotspots for Rapid Cell Line
Development
• Strategies for identification of chromosomal integration sites
which provide high and stable gene expression
• Enhancing efficiency of targeted integration using cutting-edge
technologies (Meganuclease, ZFN, TALEN and CRISP)
• Different vector designs for co-expression of light chain and
heavy chain and impact on monoclonal antibody expression and
quality
Yuan Sheng Yang, Senior Staff Research Scientist,
Bioprocessing Technology Institute, Singapore
Efficient Bioprocess Design & Scale-up
Strategies
12:10 Bioprocess Design Strategies to Increase Quality
and Efficiency
• Developing a QbD strategy in cell line and process development
• Considerations for the quality and safety of materials in contact
with biologics
• Tips to accelerate biopharmaceutical development
~ Define and align development activities for each stage
~ Streamlining technlogy transfer processes
~ Applying single-use technologies
Zhiwei Pan, Senior Director, Cell Culture Process Development,
Livzon mAbpharm, China
12:50 Networking Luncheon
______________________________________________________________________________________________
VIP Table 1: Pengfei Zhou, CEO, Wuhan YZY Biopharma
Co Ltd, China
______________________________________________________________________________________________
VIP Table 2: Andy Tsun, Senior Manager & Group Head,
Novel Drug and Cell Line Development,
Innovent Biologics, China
______________________________________________________________________________________________
VIP Table 3: XiangYang Zhu, CEO, Huaota Biopharm, China
______________________________________________________________________________________________
Exchange business cards and have an informal chat with the
above guests during the networking lunch!
2:30 Feeding and Bioreactor Strategies for Efficient Scale up
• Which cell culture process to choose – Fed-batch vs continuous-
perfusion culture review
• Case Study on Single-use disposable / miniature bioreactors for
clone selection
• High-titre cell culture processes and scale up strategies
Hao Chen, Principal Scientist, Merck, USA
3:10 Ensuring Success in Scaling up the Cell Culture Process
• Strategies to maximize productivity, enhance process
reproducibility and facilitate scale-up
• Being aware of scale-up effects on process performance and
product quality
• Questions and considerations when moving to production scale
• Tools and studies to help answer the questions
• Developing a strategy for efficient scale-up
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA
3:50 Afternoon Networking and Refreshment Break
Next-Generation Bioprocessing Trends
4:20 Insights into Next-Generation Bioprocessing
• Future of bioprocessing and trends
• Determining your key objectives: predictability, consistency,
increased titers and higher quality
• Novel process controls, biosensor tools to increase efficiency of
bioprocessing
• Smooth integration and linking of upstream and downstream
processes
• Incorporating systems biology techniques
• Latest technologies and tools in bioprocessing to accelerate
biopharmaceutical development
Moderator: Prof Rolf G Werner, Industrial Biotechnology
Department, University of Tubingen, Germany
Panelists:
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA
Hao Chen, Principal Scientist, Merck, USA
Zhiwei Pan, Senior Director, Cell Culture Process Development,
Livzon mAbpharm, China
5:00 Chairperson’s Closing Remarks &
End of Conference Day Two
PANELDISCUSSION
PANELDISCUSSION
4. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
WO R KS H O P S
DoE is central to the Quality by Design (QbD) concept because it
defines the design space of cell culture media and bioprocesses.
Therefore, this workshop will focus on the application of DoE methods
via the use of statistical software, bioprocess case studies, and hands-
on software exercise and its application to multivariate analysis (MVA)
during the optimization of culture media and bioprocesses.The case
studies will focus on CHO cell culture with data to investigate the
effects of factors such as medium components, pH, and temperature
etc on cell culture productivity and protein critical quality attributes
(CQA).
• Basic statistical concepts required for DoE
• How to design and analyze experiments for media and process
optimization using mixture, factorial, fractional factorial, and
response surface design
• How to interpret the output of experimental design software
• How to use the popular DoE software in designing and using MVA
software to analyze experiments
About Your Workshop Leader:
Dr Hung Fai Poon, R&DDirector,CellCulture, Hisun Pharmaceuticals,
China
Dr. Poon is currently the director of Cell Culture in Hisun Pharmaceuticals. He
previously worked for SAFC, Roskamp Institute in USA. He completed his
Ph.D. in Biological Chemistry at University of Kentucky, and MBA from
University of South Florida. He has years of experience in the field of biological,
analytical research, bioinformatics and proteomics. He has more than 10 years
of cell culture experience with focus on biopharmaceutical products.
He has published more than 30 peer-reviewed articles, and contributes to
more than 5 book chapters. He is currently the associate Editor for Journal
of Chemistry, Biochemistry and Molecular Biology, and Journal of
Bioinformatics and Biometrics.
PRE-CONFERENCE WORKSHOP
19 MAY 2015: 9.00am - 12:30 pm
A
PRE-CONFERENCE WORKSHOP
19 MAY 2015: 1.30pm - 5:00 pm
B
The workshop will cover the key aspects of bioprocess technology
transfer for cGMP manufacturing. It will be a short practical course
focusing on smooth scale-up, well-prepared technical transfer, and
examine how new trends and developments in bioprocessing
technology is best developed and translated to a GMP-robust
manufacturing environment.
• Process development and optimization
• Project management and communication
• Raw material and supply chain management
• Confirmation batches and process fit analysis
• Document review and approval
• Deviation and investigation
• Case Studies
About Your Workshop Leader:
Hao Chen, Principal Scientist, Merck USA
Dr. Hao Chen is a Principal Scientist in BioProcess Development at Merck
Research Laboratories (Kenilworth, NJ, USA). He currently leads the Upstream
& Recovery Process Development group for process development, scale-up,
tech transfer, and initial process characterization. His group supports cell
culture and fermentation projects from preclinical to commercial stage,
including regulatory filings. Prior to Merck, he worked on upstream
process/medium development and tech transfer for cell culture and
fermentation in various companies including Becton Dickinson (BD) and
Amylin Pharmaceuticals.
Dr. Chen received his Ph.D. degree in Chemical Engineering from Purdue
University. He also holds an MS in Biochemical Engineering and a BS in Fine
Chemical Engineering, from Zhejiang University.
POST-CONFERENCE WORKSHOP
SPECIAL FOCUS DAY
22 May 2015
Best Practices in Process Technology
Transfer and cGMP Manufacturing
Achieving Operational Excellence in
Bioprocessing: Design of Experiments
(DoE) Applications for Cell Culture
Cutting Edge Trends in
Antibody Development
9:00 Chairperson’s Opening Remarks
Weidong Jian, CSO & VP, Henlius Biopharmaceuticals, USA
9:10 Strategies for Novel Antibodies and Biosimilars
Development
• Selecting the right and appropriate clones for novel antibodies
and biosimilars
• Developing a high expression, cost-effective cell line for antibodies
• Case studies on Biosimilars development -Maintaining quality
and quantity in biosimilars cell line development
Pei Ye, Vice President, Beijing Mabworks Biotech, China
9:50 Novel Methods in Antibody Discovery and
Characterization
• Screening for the Optimal Antibody Development Candidate
Outline Profile (DCOP)
• Strategies in antibody characterization to ascertain the
identification of antibody drug candidates
• ADCs, bispecifics analytic strategies and characterization
• Case study: Biobetters and bispecific mAb initiatives
Weidong Jian, CSO & VP, Henlius Biopharmaceuticals, USA
10:30 Morning Networking and Refreshment Break
11:00 StrategiesinCellLineEngineeringofBiSpecificAntibodies
• Challenges involving finding bispecific target pairs
• Optimising the antigen expression patterns
• Identifying the target criteria for different format types
Pengfei Zhou, CEO, Wuhan YZY Biopharma Co Ltd, China
11:40 Boosting Productivity and Efficiency of Biotherapeutics
• Achieve high titers via expression vector and secretory pathways
• Using efficient resins and sequential chromatography to attain
high yields
• Attaining product efficacy and long serum half life for low doses
• High concentration liquid formulation techniques and convenient
application processes
Prof Rolf G Werner, Industrial Biotechnology Department,
University of Tubingen, Germany
12:20 Networking Lunch
1:30 Novel Strategies in Monoclonal Antibodies Targeting
GPCRs
• Difficulties in generating functional antibodies against GPCRs
and possible methods to overcome this
• An integrated Mab platform to generate functional Mabs against
GPCRs
• Development of the Mabs towards biotherapeutics
Cheng Zhang, CSO, Gmax Biopharm
2:10 Strategies in Fc Effector Function Analysis in Antibodies
• Assessing effector functions
• Ensuring similarity to original compound
• Strategies and integrated multi-assay approaches
Jingyi Xiang, Head of Bioanalytics, Eureka Pharma, USA
2:50 Afternoon Refreshements
3:20 Engineering of Antibody Drug Conjugates (ADCs)
Technologies
• Established ADC technologies including monoclonal antibody
formats, linkers and payloads
• Analyzing ADC performance- in vitro potency versus in vivo
efficacy, and safety considerations
• ADC process development and scale up CMC strategies
• Strategies to enhance ADCC activity in ADCs
4:00 Chairperson’s Closing Remarks &
End of Post-Conference Special Focus Day
C
5. Part of
IBC
LIFE SCIENCES
Geography
■ China 50%
■ Japan, Korea, HK, Taiwan 15%
■ US 10%
■ Europe 10%
■ Southeast Asia 10%
■ Rest of world 5%
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
“Over the years, the demand for
cell line development equipment,
media and reagents is likely to
increase owing to the increasing
demand for monoclonal antibodies,
rising vaccine production, and use
of innovative technologies to
develop cell lines. This market is
expected to reach $3.96 billion by
2019. However, in spite of innovative
technologies in the market,
developing stable and authentic cell
lines still remains a challenge.”
Markets and Markets,September 2014
IBC Asia’s 4th Annual Cell Line Development and Engineering Conference, provides
a platform for industry leaders from pharma/biotech, research institutes and technology
providers to discuss the challenges, trends and collaboration opportunities in conducting
cell line development in Asia.
An Under-One-Roof Approach!
In 2015, Cell Line Development & Engineering Asia will highlight exciting developments
in cell line engineering, explore efficient best practices in scaling up and bioprocessing
techniques, as well as delve into cutting edge techniques in antibody development,
all under-one-roof!
Develop robust cell lines with maximum quality, productivity and efficiency for scalability
in production. Glean effective bioprocessing and scale-up techniques, and also gain
the latest updates in antibody development with bispecifics, ADCs, and boosting
therapeutic efficiencies.
Update yourself with latest technologies to accelerate every stage of cell line development with
maximum efficiency, quality and reduced cost
Enhance cell line development in the early stages with best practices in transfection, optimizing
cell culture media, and implement advancements in clone screening and selection techniques
Gain effective bioprocess control and optimization strategies, for efficient, safe and cost
effective scale-up
Latest cutting edge updates on antibody development- novel screening strategies for
target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in
antibody therapeutics
Why You Should
Sponsor:
Position your company as a market leader
at this event and our customized
Sponsorship & Exhibition package offers
prime exposure to key decision-makers and
exceptional branding. To explore the range
of thought leadership, speaking, branding
and marketing opportunities available,
please contact Yvonne Leong
Tel: +65-6508-2489
Email: yvonne.leong@ibcasia.com.sg
WHY YOU MUST ATTEND THIS 2015
Who You Will Meet:
Industry Breakdown
■ Pharma/Biotech 55%
■ Research Institutes/Universities 15%
■ CMOs 5%
■ Technology Solution providers 20%
■ CROs 5%
About the BDP Week
The Biopharma Development & Production Week is the leading
industry platform for pharma, biotech, CMOs, CROs, research
institutes, investors, technology and industry stakeholders to meet,
network and discuss current industry trends, establish business
partnerships and be updated on investment opportunities in
China and surrounding Asia.
BIOBIO3 Conferences
in 1 Location
6. This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
4TH ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA
Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Scan the QR Code with your
smartphone and register today
Customer Service Hotline
+65 6508 2401
MAIL the attached registration
form with your cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business
Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164
Web
www.celllineasia.com
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
REGNO.200108203N
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry date, registration
and payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure
portal built into the website. To pay by phone please indicate
the contact name and details below and our Customer
Services Team will call within 24 hours to take payment.
Please do not send credit card information by email.
The personal information entered during your registration/order,
or provided by you, will be held on a database and may be
shared with companies in the Informa Group in the UK and
internationally. Occasionally, your details may be obtained from
or shared with external companies who wish to communicate
with you offers related to your business activities. If you do not
wish your details to be used for this purpose, please contact
our Database Department at Email: database@ibcasia.com.sg,
Tel: +65 6508 2400 or Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate is
welcome at no extra charge. Cancellations must be received in
writing at least 10 business days before the start of the event,
to receive a refund less 10% processing fee per registration.
The company regrets that no refund will be made available for
cancellation notifications received less than 10 business days
before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges
are to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice,
cheque or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to
ensure all details are as published. IBC assumes no further
liability or obligation, beyond the refund of the paid registration
fee, in the event of postponement or cancellation by IBC.
6 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!
■ Yes! I/We will attend the 4th Cell Line Development & Engineering Asia
19 – 22 May 2015, Grand Hyatt Shanghai, China
■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.celllineasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and
details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest
confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46262
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Main Business/Activity:
Postal Code:
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
■ I am paying by bank transfer (copy attached)
■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD
(Please tick)
Please photocopy for additional delegates
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.
Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• Registration fees are subject to the prevailing government tax.
Early Bird Rate
Register & pay on or
before 13 Mar 2014
Special Rate
Register & pay on or
before 10 Apr 2015
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
10 Apr 2015
❑ 2 Day Conference only
FEE PER DELEGATE
❑ 4 Day Package: 2 Day Conference +
All Workshops
USD 2,795 USD 2,995 USD 3,195 USD 2,595
❑ 3.5 Day Package: 2 Day Conference +
Workshop C + A or B
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
❑ 3 Day Package: 2 Day Conference +
Workshop A + B or C
❑ 2.5 Day Package: 2 Day Conference +
Workshop A or B
USD 2,595 USD 2,795 USD 2,995 USD 2,395
USD 2,395 USD 2,595 USD 2,795 USD 2,195
USD 2,095 USD 2,295 USD 2,495 USD 1,895
USD 1,795 USD 1,995 USD 2,195 USD 1,595
❑ 2 Day Conference only
❑ 4 Day Package: 2 Day Conference +
All Workshops
CNY 7,500 CNY 8,500 CNY 9,000 CNY 7,000
CNY 7,000 CNY 8,000 CNY 8,500 CNY 6,500
CNY 6,500 CNY 7,500 CNY 8,000 CNY 6,000
CNY 6,000 CNY 7,000 CNY 7,500 CNY 5,500
CNY 5,500 CNY 6,500 CNY 7,000 CNY 5,000
Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com
Domestic China Companies (Global Headquaters Located within Mainland China)
International Companies (Global Headquaters Located Outside of Mainland China)
Register 3 Delegates and
The 4th Attends For Free!
❑ 3.5 Day Package: 2 Day Conference +
Workshop C + A or B
❑ 3 Day Package: 2 Day Conference +
Workshop A + B or C
❑ 2.5 Day Package: 2 Day Conference +
Workshop A or B